Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/m3-inc" target="_blank" data-smartkarma-citation="entities:13316:1" rel="noopener">M3 Inc (2413 JP)</a> reported 3QFY03/2022 results on Wednesday. Revenue grew 16.0% YoY to JPY56.5bn (vs consensus JPY54.3bn) while OP grew 22.4% YoY to JPY22.6bn (vs consensus JPY20.6bn).</li>
<li>The company for the first time provided information on its US&amp;EU businesses. Pharma marketing &amp; research generates a majority of revenues followed by clinical trials in these regions.</li>
<li>M3 also has acquired MirVracha, a website providing marketing support services to pharmaceutical companies in Russia. MirVracha has approx. 400k members, around 60% of all physicians in the country.</li>
</ul>



M3 Inc (2413 JP) reported 3QFY03/2022 results on Wednesday. Revenue grew 16.0% YoY to JPY56.5bn (vs consensus JPY54.3bn) while OP grew 22.4% YoY to JPY22.6bn (vs consensus JPY20.6bn).
The company for the first time provided information on its US&amp;EU businesses. Pharma marketing &amp; research generates a majority of revenues followed by clinical trials in these regions.
M3 also has acquired MirVracha, a website providing marketing support services to pharmaceutical companies in Russia. MirVracha has approx. 400k members, around 60% of all physicians in the country.


M3: Covid Related Trials and Vaccination Programs Drive Earnings; Core Business Growth Slowing Down

Japan/Asia Long-Short, LightStream Research

Mio Kato

Japan/Asia Long-Short

<ul>
<li>In 2020 and 2021 we had nine conviction calls, four of which returned over 50% within just over a year.</li>
<li>Three more returned close to 40%, one returned 15% and just one was an abject failure returning -39%. </li>
<li>On average, alpha generation was 24.3% and our 2022 names are off to a good start putting up 14.7% in alpha in just over a month and a half.</li>
</ul>


In 2020 and 2021 we had nine conviction calls, four of which returned over 50% within just over a year.
Three more returned close to 40%, one returned 15% and just one was an abject failure returning -39%. 
On average, alpha generation was 24.3% and our 2022 names are off to a good start putting up 14.7% in alpha in just over a month and a half.


A Belated Look Back at Our 2020 and 2021 Conviction Calls and a Look Ahead to 2022

Equity Capital Markets

<ul>
<li>M3’s shares have dropped 37.3% over the last 12-months to JPY5,774 from JPY9,207 as the company’s earnings growth has started slowing down. </li>
<li>The Medical Platform business was a key beneficiary of pandemic which saw accelerated transformation in pharma marketing. Strong growth of Medical Platform helped offset declines in other businesses during pandemic.</li>
<li>M3’s share price has been on a correction as pandemic drove its valuations to all-time highs. M3’s recent earnings revealed that its earnings growth has started decelerating.</li>
</ul>


M3’s shares have dropped 37.3% over the last 12-months to JPY5,774 from JPY9,207 as the company’s earnings growth has started slowing down. 
The Medical Platform business was a key beneficiary of pandemic which saw accelerated transformation in pharma marketing. Strong growth of Medical Platform helped offset declines in other businesses during pandemic.
M3’s share price has been on a correction as pandemic drove its valuations to all-time highs. M3’s recent earnings revealed that its earnings growth has started decelerating.


M3: Share Price Heading into a Correction and Further 20-25% Downside Likely

<ul>
<li>Medlive is trading at HK$36.0 per share, 32.4% higher than the company’s IPO price of HK$27.2. The company’s shares have continued to trade at levels higher than its IPO price.</li>
<li>At FY2 EV/Revenue of 34.30x, Medlive appears attractive to us given the company is going through its high-growth phase alongside its proven business model and strong financials.</li>
<li>Medlive is well positioned to benefit from growing demand for digital healthcare in China which is at an early stage. </li>
</ul>


Medlive is trading at HK$36.0 per share, 32.4% higher than the company’s IPO price of HK$27.2. The company’s shares have continued to trade at levels higher than its IPO price.
At FY2 EV/Revenue of 34.30x, Medlive appears attractive to us given the company is going through its high-growth phase alongside its proven business model and strong financials.
Medlive is well positioned to benefit from growing demand for digital healthcare in China which is at an early stage. 


2022 High Conviction – Medlive: Key Beneficiary of Digital Healthcare Marketing in China

<a href="https://www.smartkarma.com/entities/m3-inc" target="_blank" data-smartkarma-citation="entities:13316:1" rel="noopener">M3 Inc (2413 JP)</a> reported its 2QFY03/2022 results on Wednesday (27th October) which saw revenues growing 29.6% YoY to JPY51.2bn while reported OP (including profit from Medlive IPO) for the quarter increased 194.1% YoY to JPY37.3bn. Excluding the impact from Medlive IPO, the adjusted OP grew 21.8% YoY to JPY15.4bn during the second quarter.<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/237/973/original/image_42895307621635358784594.png?1635358786" class="editor-image img-responsive" data-smartkarma-image-id="237973"></figure>Source: Company disclosuresThe reported revenue for 2QFY03/2022 was 4.3% higher vs consensus revenue of JPY49.1bn while reported OP for the quarter was 8.5% higher vs consensus OP of JPY34.4bn.

M3 Inc (2413 JP) reported its 2QFY03/2022 results on Wednesday (27th October) which saw revenues growing 29.6% YoY to JPY51.2bn while reported OP (including profit from Medlive IPO) for the quarter increased 194.1% YoY to JPY37.3bn. Excluding the impact from Medlive IPO, the adjusted OP grew 21.8% YoY to JPY15.4bn during the second quarter.Source: Company disclosuresThe reported revenue for 2QFY03/2022 was 4.3% higher vs consensus revenue of JPY49.1bn while reported OP for the quarter was 8.5% higher vs consensus OP of JPY34.4bn.

M3: Strong 2Q Results but Earnings Growth Starts Decelerating

Japan

M3, Inc. supplies medical information services for doctors through the Internet. The Company also supports marketing of pharmaceutical companies and medical equipment manufacturers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

M3 Inc (2413 JP)

A Belated Look Back at Our 2020 and 2021 Conviction Calls and a Look Ahead to 2022

We take a look back at our conviction calls from 2020 and 2021 to assess performance and put the strong start to our 2022 names in context.

Mio Kato

2022 High Conviction – Medlive: Key Beneficiary of Digital Healthcare Marketing in China

Medlive is well positioned to benefit from growing demand for digital healthcare in China which is at an early stage. We expect Medlive to be a key...

Shifara Samsudeen, FCMA, CGMA

M3: Strong 2Q Results but Earnings Growth Starts Decelerating

The Covid-19 outbreak supported strong growth in m3's earnings, however, with pandemic conditions easing off, earnings growth has started...

Shifara Samsudeen, FCMA, CGMA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

M3: Covid Related Trials and Vaccination Programs Drive Earnings; Core Business Growth Slowing Down

m3's 3QFY03/2022 earnings were driven by Covid-related clinical trials and vaccination projects that will come to an end once pandemic ease off....

Shifara Samsudeen, FCMA, CGMA

A Belated Look Back at Our 2020 and 2021 Conviction Calls and a Look Ahead to 2022

We take a look back at our conviction calls from 2020 and 2021 to assess performance and put the strong start to our 2022 names in context.

Mio Kato

M3: Share Price Heading into a Correction and Further 20-25% Downside Likely

M3’s share price has been on a correction as pandemic drove its valuations to all-time highs. M3's earnings growth has started decelerating our...

Shifara Samsudeen, FCMA, CGMA

2022 High Conviction – Medlive: Key Beneficiary of Digital Healthcare Marketing in China

Medlive is well positioned to benefit from growing demand for digital healthcare in China which is at an early stage. We expect Medlive to be a key...

Shifara Samsudeen, FCMA, CGMA

M3: Strong 2Q Results but Earnings Growth Starts Decelerating

The Covid-19 outbreak supported strong growth in m3's earnings, however, with pandemic conditions easing off, earnings growth has started...

Shifara Samsudeen, FCMA, CGMA